For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

CJC-1295/Ipamorelin

Also known as: CJC-1295 (no DAC) + Ipamorelin blend

A grey-market pre-mixed blend of CJC-1295 (no DAC / Modified GRF 1-29), a GHRH analog, and Ipamorelin, a selective ghrelin-receptor agonist. The blend itself is NOT clinically validated — no controlled human trial has tested this specific combination. The pharmacological rationale (GHRH + GHRP synergy for pulsatile GH amplification) is inferred from studies of other GHRH/GHRP pairs.

Where to buy · live market data

Who's worth your money for CJC-1295/Ipamorelin

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 25 scored sellers

$4.38/mg

$877 · 200mg · 99.9% purity

Best value

Lowest $/mg among scored sellers

$0.56/mg

$141 · 250mg · 99.6% purity

Most tested

3 independent COAs on file

$5.35/mg

$107 · 20mg

Average price

$5.75/mg

Sellers

41

45-day trend

-23.1%

38 of 41 sellers have a current price· 9 stale hidden· 4 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch CJC-1295/Ipamorelin

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About CJC-1295/Ipamorelin

CAS

Molecular formula

Typical dose range

100–300 mcg of each component (CJC-1295 no DAC + Ipamorelin) per injection, 1–2x daily subcutaneous, typically on empty stomach

Half-life

CJC-1295 (no DAC): ~30 minutes; Ipamorelin: ~2 hours

Independent evidence

COAs for CJC-1295/Ipamorelin

82 third-party tests across 31 vendors. Each card links to the full report.

All 82 COAs for CJC-1295/Ipamorelin →
Measured purity 98.7%–100.0% across 38 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.88 %
Jul 2026
Freedom Diagnostics Moderate

For

CJC-1295/Ipamorelin

by Rescue Research USA· batch RR-CJCIPA2607

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

CJC-1295/Ipamorelin

by OROS Research· batch OR-LPCJCIPA20-626-B3

Aggregated · 3rd-party listing
99.87 %
Jun 2026
Freedom Diagnostics Moderate

For

CJC-1295/Ipamorelin

by Peptide Supply Co.· batch CI10 06032026

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

CJC-1295/Ipamorelin

by OROS Research· batch OR-LPCJCIPA10-526-B10

Aggregated · 3rd-party listing
99.85 %
May 2026
Freedom Diagnostics Moderate

For

CJC-1295/Ipamorelin

by Secra Labs· batch SL-202605-CJCIPA

Aggregated · 3rd-party listing
99.96 %
May 2026
Freedom Diagnostics Moderate

For

CJC-1295/Ipamorelin

by Modern Research Peptides· batch YCJLS2581

Aggregated · 3rd-party listing
99.96 %
May 2026
Freedom Diagnostics Moderate

For

CJC-1295/Ipamorelin

by Modern Research Peptides· batch RCJLS3422

Aggregated · 3rd-party listing
99.00 %
May 2026
Ethos Analytics Strong · HPLC

For

CJC-1295/Ipamorelin

by OROS Research· batch OR-LPCJCIPA10-526-B9

Aggregated · 3rd-party listing
99.57 %
May 2026
ILS Labs Strong

For

Ipamorelin/CJC-1295

by Sunrise Bioresearch· batch CP10MAY26-01

Aggregated · 3rd-party listing
99.53 %
Apr 2026
ILS Labs Strong

For

CJC/IPA

by Riptide Wellness· batch RWCP-10-1003

Aggregated · 3rd-party listing
99.60 %
Apr 2026
ILS Labs Strong

For

CJC / Ipamorelin

by NG Peptide· batch CJPA10-03

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

CJC-1295/Ipamorelin

by OROS Research· batch OR-LPCJCIPA10-326-B8

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

CJC-1295/Ipamorelin

by OROS Research· batch OR-LPCJCIPA20-326-B2

Aggregated · 3rd-party listing
99.79 %
Apr 2026
Kovera Labs

For

CJC-1295 (No DAC)/Ipamorelin

by Ion Peptide· batch CP10-04042026

Aggregated · 3rd-party listing
99.93 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

Ipamorelin/CJC-1295

by Blank Peptides· batch 665394

Aggregated · 3rd-party listing
99.94 %
Apr 2026
Biogenica Labs · HPLC

For

CJC-1295 / Ipamorelin (No DAC)

by Amino Club· batch CIP0001

Aggregated · 3rd-party listing
99.90 %
Apr 2026
BTLabs Moderate · HPLC

For

CJC-1295/Ipamorelin

by Crush Research· batch CR-CJIP20-2603-1

Aggregated · 3rd-party listing
99.82 %
Mar 2026
Kovera Labs

For

CJC-1295 (No DAC)/Ipamorelin

by Ion Peptide· batch CP10-03262026

Aggregated · 3rd-party listing
99.75 %
Mar 2026
Kovera Labs

For

CJC-1295 (No DAC)/Ipamorelin

by Ion Peptide· batch CP-10-03242026

Aggregated · 3rd-party listing
99.87 %
Mar 2026
Kovera Labs

For

CJC-1295 (No DAC)/Ipamorelin

by Mile High Compounds· batch CIB-010-MH-01

Aggregated · 3rd-party listing
99.92 %
Mar 2026
Kovera Labs

For

CJC-1295 (No DAC)/Ipamorelin

by Glacier Aminos· batch CJIP10GA-03

Aggregated · 3rd-party listing
99.80 %
Feb 2026
Vanguard Laboratory Strong

For

CJC-1295/Ipamorelin

by Peptidology· batch 1668

Aggregated · 3rd-party listing
99.79 %
Feb 2026
Freedom Diagnostics Moderate

For

CJC-1295 + Ipamorelin (no dac)

by Nox Amino· batch NA-CP0226-01

Aggregated · 3rd-party listing
99.35 %
Feb 2026
Vanguard Laboratory Strong

For

CJC-1295/Ipamorelin

by Peptidology· batch 1669

Research depth

6 citations indexed for CJC-1295/Ipamorelin

All research on CJC-1295/Ipamorelin →

review · 2026

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications

Background Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.

review · 2026

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.

review · 2026

Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks

Unregulated peptide use is emerging as a digitally mediated public health concern.

review · 2026

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

Background Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients.

review · 2026

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.

Study · 2022

Guideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms